On September 22, 2025, BioCardia, Inc. reported a successful preliminary clinical meeting with Japan’s PMDA regarding the CardiAMP Heart Failure Trial results, paving the way for future regulatory submission. This event is significant for investors, indicating progress in the approval process, and carries a positive sentiment.